MarketPulse

clinical-stage company

2 articles
The Motley FoolThe Motley Fool··Seena Hassouna

ENAVATE's Zenas Stake Surge Masks Real Story: Obexelimab Pipeline

ENAVATE deepens Zenas BioPharma stake to $142.3M. Key catalyst: obexelimab Phase 2 lupus data and Q2 2026 FDA submission.
ZBIOFDA approvalautoimmune diseases
The Motley FoolThe Motley Fool··Lawrence Rothman, Cfa

Soleus Capital Elevates Celcuity to Third-Largest Position With Major Share Purchase

Soleus Capital significantly increased its Celcuity stake to 1.8 million shares, making it their third-largest position worth $180 million as the biotech stock surged 745% yearly.
PRAXCELCKRYSNVCRportfolio allocationinstitutional buying